FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Harold Bays

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Harold E Bays; Rene A Braeckman; Christie M Ballantyne; William G Stirtan; Paresh N Soni
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
Harold E Bays
Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies.
Harold E Bays; Rene A Braeckman; John J Kastelein; James D Otvos; Christie M Ballantyne; William G Stirtan; Paresh N Soni
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Harold Bays (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Harold E Bays; Rene A Braeckman; Christie M Ballantyne; William G Stirtan; Paresh N Soni
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2013;13(1):37-46.
2012: Harold E Bays
Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies.
The American journal of cardiology 2012;110(9 Suppl):4B-12B.
2012: Harold E Bays; Rene A Braeckman; John J Kastelein; James D Otvos; Christie M Ballantyne; William G Stirtan; Paresh N Soni
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
Journal of clinical lipidology 2012;6(6):565-72.
2012: W Virgil Brown; Kevin C Maki; Harold E Bays; Robert A Wild
Planning a clinical trial.
Journal of clinical lipidology 2012;6(6):484-95.
2012: Christie M Ballantyne; Harold E Bays; Rene A Braeckman; Jonathan L Isaacsohn; John J Kastelein; Evan Stein; Paresh N Soni
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
The American journal of cardiology 2012;110(7):984-92.
2012: Darbie Maccubbin; Christine McCrary Sisk; Anders G Olsson; Waheeda Sirah; Jennifer Weimer Anderson; Harold E Bays; Fabian Chen; Uma Kher; Yale B Mitchel
Effectiveness and safety of laropiprant on niacin-induced flushing.
The American journal of cardiology 2012;110(6):817-22.
2012: Harold E Bays; Qian Dong; Jianxin Lin; Arvind Shah; Christine McCrary Sisk; Darbie Maccubbin
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;12(3):197-206.
2012: Harold E Bays
Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients.
Diabetes, metabolic syndrome and obesity : targets and therapy 2012;5():125-34.
2011: Harold E Bays; Steven R Bird; Scott E Conard; Lawrence A Leiter; Robert S Lowe; Andrew M Tershakovec
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
International journal of cardiology 2011;153(2):141-7.
2011: Harold E Bays; Yun-Jung Choi; David B Karpf; BORIS KERZNER; Ronald M Krauss; Thomas Littlejohn; Sue Naim; Sherwyn Schwartz; Xueyan Wang; Brian K Roberts
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
The Journal of clinical endocrinology and metabolism 2011;96(9):2889-97.
2011: Harold E Bays; Rene A Braeckman; Jonathan L Isaacsohn; John J Kastelein; Christie M Ballantyne; Paresh N Soni
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
The American journal of cardiology 2011;108(5):682-90.
2011: Harold E Bays
Adiposopathy is "sick fat" a cardiovascular disease?
Journal of the American College of Cardiology 2011;57(25):2461-73.
2011: Harold E Bays
Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
Expert review of cardiovascular therapy 2011;9(3):265-77.
2011: Harold E Bays; Kevin C Maki; Kathy Schmitz
Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2011;17(2):218-25.
2010: Harold E Bays; J M Gonzalez-Campoy; A B Schorr
What men should know about metabolic syndrome, adiposopathy and 'sick fat'.
International journal of clinical practice 2010;64(13):1735-9.
2010: Harold E Bays
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Expert review of cardiovascular therapy 2010;8(12):1777-801.
2010: Harold E Bays; Arvind Shah; Jianxin Lin; Christine McCrary Sisk; John F Paolini; Darbie Maccubbin
Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Journal of clinical lipidology 2010;4(6):515-21.
2010: Harold E Bays; K C Maki; K Schmitz
The Bile Acid Sequestrant Acceptability scale validation study.
International journal of clinical practice 2010;64(10):1393-7.
2010: Harold E Bays; Kevin C Maki; James McKenney; Rose Snipes; Amy Meadowcroft; Rosemary Schroyer; Ralph T Doyle; Evan Stein
Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
Current medical research and opinion 2010;26(4):907-15.
2010: James McKenney; Harold E Bays; Michael Koren; Christie M Ballantyne; John F Paolini; Yale Mitchel; Abigaile Betteridge; Olga Kuznetsova; Aditi Sapre; Christine McCrary Sisk; Darbie Maccubbin
Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
Journal of clinical lipidology 2010;4(2):105-112.e1.
2010: Harold E Bays; James McKenney; Kevin C Maki; Ralph T Doyle; Roderick N Carter; Evan Stein
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
Mayo Clinic proceedings. Mayo Clinic 2010;85(2):122-8.
2009: Harold E Bays; Christie Ballantyne
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Current opinion in lipidology 2009;20(6):467-76.
2009: Harold E Bays
Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
Expert review of cardiovascular therapy 2009;7(11):1429-45.
2009: Harold E Bays; Kevin C Maki; Ralph T Doyle; Evan Stein
The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Postgraduate medicine 2009;121(5):145-50.
2009: Harold E Bays; B Laferrère; J Dixon; L Aronne; J M González-Campoy; C Apovian; B M Wolfe
Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?
International journal of clinical practice 2009;63(9):1285-300.
2009: Harold E Bays
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
Current medical research and opinion 2009;25(3):671-81.
2009: Harold E Bays; Debbra D Bazata; Kathleen M Fox; Susan Grandy; James R Gavin
Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scale.
Nutrition journal 2009;8():57.
2009: Harold E Bays; Darbie Maccubbin; Alan G Meehan; Olga Kuznetsova; Yale B Mitchel; John F Paolini
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Clinical therapeutics 2009;31(1):115-22.
2009: Harold E Bays
"Sick fat," metabolic disease, and atherosclerosis.
The American journal of medicine 2009;122(1 Suppl):S26-37.
2009: Harold E Bays; D J Rader
Does nicotinic acid (niacin) lower blood pressure?
International journal of clinical practice 2009;63(1):151-9.
2008: Harold E Bays; Peter H Jones; Syed M Mohiuddin; Maureen T Kelly; Hsiaoming Sun; Carolyn M Setze; Susan M Buttler; Darryl J Sleep; James C Stolzenbach
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
Journal of clinical lipidology 2008;2(6):426-35.
2008: D Maccubbin; Harold E Bays; A G Olsson; V Elinoff; A Elis; Yale B Mitchel; W Sirah; A Betteridge; R Reyes; Q Yu; O Kuznetsova; C McCrary Sisk; R C Pasternak; John F Paolini
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
International journal of clinical practice 2008;62(12):1959-70.
2008: John F Paolini; Harold E Bays; Christie M Ballantyne; Michael Davidson; Richard Pasternak; Darbie Maccubbin; Josephine M Norquist; Eseng Lai; M Gerard Waters; Olga Kuznetsova; Christine McCrary Sisk; Yale B Mitchel
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Cardiology clinics 2008;26(4):547-60.
2008: Harold E Bays; Ronald B Goldberg; Kenneth E Truitt; Michael R Jones
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
Archives of internal medicine 2008;168(18):1975-83.
2008: Harold E Bays; Aditi Sapre; William Taggart; Ji Liu; Rachel Capece; Andrew M Tershakovec
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.
Current medical research and opinion 2008;24(10):2953-66.
2008: John F Paolini; Yale B Mitchel; R Reyes; S Thompson-Bell; Q Yu; Eseng Lai; Douglas J Watson; Josephine M Norquist; C McCrary Sisk; Harold E Bays
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial.
International journal of clinical practice 2008;62(6):896-904.
2008: Harold E Bays
Safety of niacin and simvastatin combination therapy.
The American journal of cardiology 2008;101(8A):3B-8B.
2008: Harold E Bays; David Neff; Joanne E Tomassini; Andrew M Tershakovec
Ezetimibe: cholesterol lowering and beyond.
Expert review of cardiovascular therapy 2008;6(4):447-70.
2008: Harold E Bays; Richard H Chapman; Kathleen M Fox; Susan Grandy
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.
Current medical research and opinion 2008;24(4):1179-86.
2008: Harold E Bays
Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
Drugs of today (Barcelona, Spain : 1998) 2008;44(3):205-46.
2008: Harold E Bays; Ann P Tighe; Richard Sadovsky; Michael H Davidson
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Expert review of cardiovascular therapy 2008;6(3):391-409.
2008: Harold E Bays; J Michael González-Campoy; George A Bray; Abbas E Kitabchi; Donald A Bergman; Alan Bruce Schorr; Helena W Rodbard; Robert R Henry
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
Expert review of cardiovascular therapy 2008;6(3):343-68.
2008: John F Paolini; Yale B Mitchel; Robert Reyes; Uma Kher; Eseng Lai; Douglas J Watson; Josephine M Norquist; Alan G Meehan; Harold E Bays; Michael Davidson; Christie M Ballantyne
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
The American journal of cardiology 2008;101(5):625-30.
2008: Peter H Jones; Harold E Bays; Michael H Davidson; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Clinical drug investigation 2008;28(10):625-34.
2007: Harold E Bays; Jennifer McElhattan; Brian S Bryzinski
A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2007;4(3):181-93.
2007: Kathleen M Fox; Sanjay K Gandhi; Robert L Ohsfeldt; James W Blasetto; Harold E Bays
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Current medical research and opinion 2007;23(9):2125-33.
2007: Harold E Bays; David E Cohen
Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.
Current medical research and opinion 2007;23(7):1673-84.
2007: James M McKenney; Peter H Jones; Harold E Bays; Robert H Knopp; Moti L Kashyap; Gary E Ruoff; Mark E McGovern
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Atherosclerosis 2007;192(2):432-7.
2007: Harold E Bays; R H Chapman; S Grandy
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.
International journal of clinical practice 2007;61(5):737-47.
2007: Harold E Bays
Safety considerations with omega-3 fatty acid therapy.
The American journal of cardiology 2007;99(6A):35C-43C.
2007: John R Guyton; Harold E Bays
Safety considerations with niacin therapy.
The American journal of cardiology 2007;99(6A):22C-31C.
2007: Harold E Bays; Peter H Jones
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.
Vascular health and risk management 2007;3(5):733-42.
2007: Harold E Bays; Debbra D Bazata; Nathaniel G Clark; James R Gavin; Andrew J Green; Sandra Lewis; Michael L Reed; Walter Stewart; Richard H Chapman; Kathleen M Fox; Susan Grandy
Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes).
BMC public health 2007;7():277.
2006: Harold E Bays; James Rhyne; Stacey Abby; Yu-Ling Lai; Michael Jones
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Current medical research and opinion 2006;22(11):2191-200.
2006: Harold E Bays
Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
The American journal of cardiology 2006;98(4A):71i-76i.
2006: James M McKenney; Michel Farnier; Kwok-Wing Lo; Harold E Bays; Inna Perevozkaya; Gary Carlson; Michael J Davies; Yale B Mitchel; Barry Gumbiner
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
Journal of the American College of Cardiology 2006;47(8):1584-7.
2006: Harold E Bays
Statin safety: an overview and assessment of the data--2005.
The American journal of cardiology 2006;97(8A):6C-26C.
2006: Harold E Bays; Michael Davidson; Michael R Jones; Stacey L Abby
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
The American journal of cardiology 2006;97(8):1198-205.
2006: Harold E Bays; Carlos A Dujovne
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.
Current atherosclerosis reports 2006;8(2):144-56.
2006: Harold E Bays
The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy.
Drugs in R&D 2006;7(5):289-302.
2005: James M McKenney; Michael H Davidson; Joseph Saponaro; Paul D Thompson; Harold E Bays
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
Journal of cardiovascular pharmacology 2005;46(5):594-9.
2005: Harold E Bays; James McKenney; Michael Davidson
Torcetrapib/atorvastatin combination therapy.
Expert review of cardiovascular therapy 2005;3(5):789-820.
2005: Michael H Davidson; Harold E Bays; James Rhyne; Evan Stein; Keith Rotenberg; Ralph Doyle
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Clinical therapeutics 2005;27(6):715-27.
2005: Harold E Bays
Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything.
Expert review of cardiovascular therapy 2005;3(3):393-404.
2005: Prakash C Deedwania; Donald B Hunninghake; Harold E Bays; Peter H Jones; Valerie A Cain; James W Blasetto
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
The American journal of cardiology 2005;95(3):360-6.
2005: Harold E Bays; Mark E McGovern
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Preventive cardiology 2005;8(4):226-33.
2004: Harold E Bays; Leiv Ose; Neil Fraser; Diane L Tribble; Katherine Quinto; Robert Reyes; Amy O Johnson-Levonas; Aditi Sapre; Steven R Donahue
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Clinical therapeutics 2004;26(11):1758-73.
2004: Harold E Bays
Metabolic syndrome: what might be occurring?
Managed care (Langhorne, Pa.) 2004;13(10 Suppl):13-6.
2004: Harold E Bays
Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
Expert review of cardiovascular therapy 2004;2(4):485-501.
2003: Harold E Bays; Evan A Stein
Pharmacotherapy for dyslipidaemia--current therapies and future agents.
Expert opinion on pharmacotherapy 2003;4(11):1901-38.
2003: Harold E Bays; James M McKenney; Carlos A Dujovne; Helmut Schrott; Michael J Zema; Jack Nyberg; Diane E MacDougall
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
The American journal of cardiology 2003;92(5):538-43.
2003: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The American journal of cardiology 2003;92(2):152-60.
2003: Harold E Bays; Carlos A Dujovne
Colesevelam HCl: a non-systemic lipid-altering drug.
Expert opinion on pharmacotherapy 2003;4(5):779-90.
2003: Robert H Knopp; H Gitter; T Truitt; Harold E Bays; C V Manion; Leslie Lipka; LeBeaut Pierre Alexandre; Ramachandran Suresh; Bo Yang; Enrico Veltri
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
European heart journal 2003;24(8):729-41.
2003: Harold E Bays; Carlos A Dujovne; Mark E McGovern; T Eric White; Moti L Kashyap; A Gene Hutcheson; John R Crouse
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
The American journal of cardiology 2003;91(6):667-72.
2003: Harold E Bays; Mark E McGovern
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Preventive cardiology 2003;6(4):179-88.
2003: Jonathan L Isaacsohn; Donald B Hunninghake; Helmut Schrott; Carlos A Dujovne; Robert Knopp; Stuart R Weiss; Harold E Bays; John R Crouse; Michael H Davidson; Leonard M Keilson; James McKenney; Stanley G Korenman; Adrian S Dobs; Evan Stein; Ronald M Krauss; Darbie Maccubbin; Meehyung Cho; Diane J Plotkin; Yale B Mitchel
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Clinical cardiology 2003;26(1):18-24.
2002: W Virgil Brown; Harold E Bays; David R Hassman; James McKenney; Rohini R Chitra; Howard Hutchinson; Elinor Miller
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
American heart journal 2002;144(6):1036-43.
2002: Harold E Bays
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
The American journal of cardiology 2002;90(10B):30K-43K.
2002: Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
The American journal of cardiology 2002;90(10):1084-91.
2002: Harold E Bays
Ezetimibe.
Expert opinion on investigational drugs 2002;11(11):1587-604.
2002: Harold E Bays; Evan A Stein; Arvind K Shah; Darbie Maccubbin; Yale B Mitchel; Michele Mercuri
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
The American journal of cardiology 2002;90(9):942-6.
2002: Harold E Bays; Carlos A Dujovne
Anti-obesity drug development.
Expert opinion on investigational drugs 2002;11(9):1189-204.
2002: Moti L Kashyap; Mark E McGovern; Kathleen Berra; John R Guyton; Peter O Kwiterovich; Wayne L Harper; Phillip D Toth; Laurence K Favrot; BORIS KERZNER; Stephen D Nash; Harold E Bays; Phillip D Simmons
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
The American journal of cardiology 2002;89(6):672-8.
2002: Harold E Bays; Carlos A Dujovne
Pharmacotherapy of obesity: currently marketed and upcoming agents.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2002;2(4):245-53.
2001: Harold E Bays; P B Moore; M A Drehobl; S Rosenblatt; P D Toth; Carlos A Dujovne; Robert H Knopp; Leslie Lipka; LeBeaut Pierre Alexandre; Bo Yang; Lillian Mellars; C Cuffie-Jackson; Enrico Veltri
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.
Clinical therapeutics 2001;23(8):1209-30.
2001: Carlos A Dujovne; Harold E Bays; Michael H Davidson; Robert Knopp; Donald B Hunninghake; E A Stein; A C Goldberg; P Jones; Leslie Lipka; C Cuffie-Jackson
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
Journal of clinical pharmacology 2001;41(1):70-8.
2000: Michael H Davidson; Evan A Stein; Donald B Hunninghake; Leiv Ose; Carlos A Dujovne; William Insull; Marcelo C Bertolami; Stuart R Weiss; John J P Kastelein; Russell S Scott; S Campodónico; Ivan D Escobar; Helmut Schrott; Harold E Bays; Michael Stepanavage; M Wu; A C Tate; MR Melino; Debra Kush; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):253-62.
2000: Adrian S Dobs; Helmut Schrott; Michael H Davidson; Harold E Bays; Evan A Stein; Debra Kush; M Wu; Yale B Mitchel; R D Illingworth
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.
Metabolism: clinical and experimental 2000;49(9):1234-8.
2000: Evan Stein; Diane J Plotkin; Harold E Bays; Michael Davidson; Carlos A Dujovne; Stanley G Korenman; Michael Stepanavage; Michele Mercuri
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
The American journal of cardiology 2000;86(4):406-11.
1999: Harold E Bays; Carlos A Dujovne
Lipid-altering drugs in development.
Drugs in R&D 1999;1(6):463-9.
1998: Harold E Bays; Carlos A Dujovne
Drug interactions of lipid-altering drugs.
Drug safety : an international journal of medical toxicology and drug experience 1998;19(5):355-71.
1998: Evan A Stein; Michael H Davidson; Adrian S Dobs; Helmut Schrott; Carlos A Dujovne; Harold E Bays; Stuart R Weiss; MR Melino; Michael Stepanavage; Yale B Mitchel
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
The American journal of cardiology 1998;82(3):311-6.
1994: Harold E Bays; A M Lansing
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
The Journal of the Kentucky Medical Association 1994;92(3):105-8.
1994: Harold E Bays; Carlos A Dujovne
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1994;43():9-41.
1993: Harold E Bays; Carlos A Dujovne; J B Mays
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease.
The Journal of the Kentucky Medical Association 1993;91(11):498-500.
1992: Harold E Bays; Carlos A Dujovne; A M Lansing
Drug treatment of dyslipidemias: practical guidelines for the primary care physician.
Heart disease and stroke : a journal for primary care physicians 1992;1(6):357-65.
1992: Harold E Bays; Carlos A Dujovne
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority.
Postgraduate medicine 1992;91(5):162-4, 167-8, 171-2 passim.
1988: Harold E Bays; M A Pfeifer
Peripheral diabetic neuropathy.
The Medical clinics of North America 1988;72(6):1439-64.